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Pathologic findings of initial biopsies reflect the outcomes of
membranous nephropathy.
Background. A considerable diversity of prognosis is seen
with idiopathic membranous nephropathy (IMN). The initial
factors affecting long-term outcome remain unclear.
Methods. We studied retrospectively 105 patients with IMN
who had been followed up for at least 5 years, or until end-stage
renal failure (ESRF) (primary outcome), or death (secondary
outcome). We analyzed the initial clinicopathologic factors af-
fecting primary and secondary outcomes. We assigned the pa-
tients to two groups and one subgroup, based on the electron
microscopic findings. The groupings were: homogeneous type
with synchronous electron dense deposits; homogeneous type
with large dense deposits (deep subgroup); and heterogeneous
type with various phases of dense deposits.
Results. No differences in the initial clinicopathologic states
were seen between the homogeneous (N = 60) and hetero-
geneous types (N = 45), apart from hypertension and disease
history before biopsy. In the homogeneous type, only one pa-
tient developed ESRF, which was drug-induced, and remission
occurred earlier than in the heterogeneous type. With regard
to secondary outcomes, increased age, male gender, heteroge-
neous type, and deep subgroup were independent risk factors.
There were no significant differences attributable to therapeutic
regime with respect to primary or secondary outcome in either
group.
Conclusion. Our results indicate that an electron microscopic
classification, at initial biopsy, as heterogeneous type or deep
subgroup type with dense deposits are independent indicators
of poor prognosis in IMN.
Human idiopathic membranous nephropathy (IMN)
shows considerable heterogeneity with regard to end-
stage renal failure (ESRF) (primary outcome), and ESRF
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or patient death (secondary outcome). Overall, 40% of
Japanese nephrotic patients, and one third to one half
of the patients in other countries, develop ESRF within
20 years of onset, or die from complications such as
infection, cardiovascular incidents, or malignancy. On
the other hand, about 25% of patients with IMN un-
dergo spontaneous remission [1–5]. Conflicting results
have been obtained for the therapeutic effects of various
treatments, due to an inability to demarcate the different
prognostic groups [4, 5].
Recent reports emphasize the prognostic value, for
both primary and secondary outcomes, of tubuloint-
erstitial changes (cellular infiltration and fibrosis) [6,
7], glomerular changes with focal segmental sclerosis
(FSGS) [8], and advanced histologic stage of the electron
dense deposits [9] (III to IV according to the criteria of
Ehrenreich et al [10]). We previously reported differences
in clinical responses to high-dose intravenous immune
globulin therapy among subtypes of IMN defined by
their pattern of subepithelial electron dense deposits [11].
Rosen, Tornroth, and Bernard [12] had previously delin-
eated four groups according to their morphologic and
clinical patterns; short with one generation of deposits,
short/repeated, long/rapid, and long/slow. We simplified
this classification by combining those with one genera-
tion of deposits, short/repeated and long/rapid into the
homogeneous type and designating the long/slow cases
as the heterogeneous type on the basis of synchronic-
ity and clinical course. However, the exact renal and pa-
tient outcome dependence on the pattern of subepithelial
electron dense deposits in the first renal biopsy remain
unclear.
In this study, we retrospectively analyzed clinicopatho-
logic factors in 105 Japanese patients with IMN who were
followed up for at least 5 years after initial renal biopsy.
We report that electron microscopic findings of the het-
erogeneous type with different phases of dense deposits,
or the deep subgroup type, together with FSGS are inde-
pendent indicators of poor prognosis.
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METHODS
Patients and treatments
We retrospectively enrolled 105 Japanese patients
(65 men and 40 women, aged 18 to 80 years, mean
46.7 years) with IMN, who were admitted to the First
Department of Internal Medicine of Kanazawa Univer-
sity Hospital, or its affiliated hospitals, between 1965 and
1995. We followed these patients for at least 5 years,
or until ESRF or death (from 9 to 330 months, mean
116.1 months). Diagnosis was confirmed in all patients by
percutaneous needle renal biopsy. Patients who, accord-
ing to the clinical and laboratory findings, had secondary
membranous nephropathies such as lupus nephritis, or
membranous nephropathies related to hepatitis B virus
or malignancy, were excluded from the study. The patients
were treated nonrandomly, depending on the judgment
of the doctor in charge of each case, with either no im-
munosuppressant, or supportive therapy (N = 17); cor-
ticosteroid (steroid) alone (N = 15); cyclophosphamide
with steroid (N = 24); high-dose intravenous immune
globulin with or without steroid (N = 29); or cyclosporine
with or without steroid (N = 20). There were no signif-
icant differences in clinical background between groups.
Informed consent was obtained for all renal biopsies and
treatments.
Clinical status was assessed according to Japanese clin-
ical categories employing the criteria of nephrotic state,
presence of marked proteinuria greater than 3.5 g/day or
3+ (300 mg/dL) to 4+ (1000 mg/dL) by Multistics (Miles,
Tokyo, Japan) and hypoalbuminemia (less than 30 g/L);
incomplete remission type II (i.e., normal serum albu-
min levels) (greater than 30 g/L) with a mean 24-hour
proteinuria of 1.0 g to 3.5 g for 7 consecutive days or
2+ (100 mg/dL) to 3+ (300 mg/dL); incomplete remis-
sion type I (i.e., normal serum albumin levels) (greater
than 30 g/L) with a mean daily proteinuria of less than
1.0 g for 7 consecutive days or + (30 mg/dL); and com-
plete remission (i.e., daily proteinuria of less than 0.2 g
with normal serum albumin levels). Renal dysfunction
was defined as a serum creatinine level of greater than
132.6 lmol/L (1.5 mg/dL) or a glomerular filtration rate
(GFR), as determined by endogenous creatinine clear-
ance, of less than 60 mL/min. ESRF was defined as the
need for hemodialysis, peritoneal dialysis, or renal trans-
plantation. For the purpose of analysis, we defined re-
mission as improvement of clinical status to the point of
incomplete remission type I according to the criterion
of good long-term renal outcome in the Japanese coop-
erative study (N = 1008, unpublished data in English).
Primary outcome was defined as ESRF and secondary
outcome as ESRF or patient’s death.
Histopathologic studies
Light microscopic examination.For light microscopic
examination, renal biopsy specimens were fixed in 10%
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Fig. 1. Subtypes of idiopathic membranous nephropathy. (A) Homo-
geneous type (original magnification ×3000). (B) Heterogeneous type
(original magnification ×3000). (C) Deep subtype of homogeneous type
(original magnification ×3000).
phosphate-buffered formalin (pH 7.4), embedded in
paraffin, and sliced into 4 lm sections. These specimens
were stained with hematoxylin and eosin (H&E), peri-
odic acid-Schiff reagent (PAS), Mallory-azan, and peri-
odic acid silver methenamine (PAM), and examined by
light microscopy, with the emphasis on capillary lesions.
The frequency of segmental sclerosis (FSGS) was deter-
mined. Interstitial infiltration, tubular atrophy, and fibro-
sis in the interstitium were graded as follows: absent (0),
faint (0.5), patchy (1), zonal (2), and diffuse (3).
Renal tissue specimens were examined by two patholo-
gists with no knowledge of the patients’ clinical condition
to establish the diagnosis by standard pathologic methods
alone.
Electron microscopic examination.A total of 158 speci-
mens were fixed with glutaraldehyde and osmium tetrox-
ide, embedded in Epon 812 (Oken Shoji Co., Tokyo,
Japan), sliced into 0.1 lm sections, double-stained with
uranyl acetate and lead citrate, and examined under the
electron microscope (Hitachi H-600, Hitachi Co., Tokyo,
Japan). For this study, specimens were examined with em-
phasis on the phase and synchronicity of subepithelial
and intramembranous electron dense deposits, as pre-
viously reported [11]. We modified the classification of
Rosen, Tornroth, and Bernard [12] and arbitrarily clas-
sified specimens showing synchronous electron dense
deposits with a single phase as homogeneous type, and
others having various phases of electron dense deposits
as heterogeneous type (Fig. 1). In subanalyses for sec-
ondary outcome, we further classified seven patients of
homogeneous type as a deep subgroup, due to large phase
II depositions with prolonged nephrotic state (similar to
Rosen’s long/rapid type).
The changes of subepithelial electron dense deposits
were compared in the 44 patients who underwent a sec-
ond renal biopsy at 1 to 201 months posttreatment.
Statistical analysis
Statistical analyses were performed using the chi-
square test, the analysis of variance (ANOVA) test, the
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Table 1. Case profiles of 105 patients with idiopathic membranous nephropathy (IMN)
Idiopathic N = 105 ESRF N = 12 Non-ESRF N = 93 P value
Age years 46.7 ± 1.4 45.2 ± 4.4 46.8 ± 1.5 NS
Male/female 64/41 7/5 57/36 NS
After onset months 21.9 ± 3.1 32.3 ± 10.3 19.7 ± 3.1 NS
Follow-up months 116.1 ± 7.7 106.6 ± 19.3 118.9 ± 8.3 NS
Nephrotic state % 71.4 100.0 67.6 <0.05
24-hr creatinine clearance 95.6 ± 2.8 85.8 ± 8.2 96.4 ± 2.8 NS
Hypertension % 20.0 75.0 12.5 <0.001
Electron microscope (homo/hetero) 60/45 1/11 59/34 <0.001
Theroy
No or supportive 17 0 17 NS
Steroids alone 15 4 11
Cyclophosphamide + steroids 24 2 22
Immunoglobulin ± steroids 29 4 25
Cyclosporine A ± steroids 20 2 18
ESRF is end-stage renal failure; NS is not significant.
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Fig. 2. The outcomes of nephrotic and non-
nephrotic patients with idiopathic membra-
nous nephropathy (IMN). (A) Renal survival
rates in nephrotic and nonnephrotic patients.
(B) Renal or patient death in nephrotic or
nonnephrotic patients by Kaplan-Meier life-
table method. Broad and thin lines represent
the nephrotic patients and nonnephrotic pa-
tients, respectively.
Kruskal-Wallis test, Pearson and Spearman’s correla-
tion coefficient for the analyses of parametric and non-
parametric data, the Mantel-Cox log rank test, and the
Kaplan-Meier life-table method. The independent risk
factors for primary and secondary outcomes were studied
with the Cox proportional hazards model. Values were
expressed as mean ± standard error of mean (SEM).
P values of less than 0.05 were considered statistically
significant. SAS software was used for the statistical cal-
culations (SAS Institute, Cary, NC, USA).
RESULTS
Patients’ background and outcomes
At the time of renal biopsy, 75 patients were in
a nephrotic state and 30 in a nonnephrotic state
(Table 1). During the follow-up period, 12 patients devel-
oped ESRF (11.4%) and 18 died from nonrenal diseases.
The latter comprised five patients with infectious diseases
(including pneumonia and infectious aortic aneurysm
during immunosuppressive therapy whether they were in
remission or not), seven with malignancies (three gastric
cancers, one pancreatic cancer, one lung cancer and one
laryngeal cancer that were detected more than 24 months
from the onset of membraneous nephropathy, with a
mean of 98.8 months, and one leukemia at 11 months
after cyclophosphamide treatment) and six with vascu-
lar diseases. In the nephrotic patients, the mean 75%
renal survival time derived from the estimated proba-
bility curve based on Kaplan-Meier analysis was 243 ±
81 months (Fig. 2A). However, there were no signifi-
cant differences in primary and secondary outcomes, or
in final clinical state, between subgroups depending on
whether they received no immunosuppressive or support-
ive therapy, were treated with steroid alone, steroid with
cyclophosphamide, intravenous immunoglobulin, or cy-
closporine with or without steroid. Immunoglobulin and
cyclosporine did tend, however, to induce earlier remis-
sion (Table 2).
Different primary and secondary outcomes
in the subtypes of IMN
There was no difference in initial clinicopathologic
states between the patients with ESRF (N = 12) and
without ESRF (N = 93), except for nephrotic syn-
drome, hypertension, and electron microscopic findings
(Table 1). GFR at initial renal biopsy tended to be lower
in the patients with ESRF than without ESRF (86 mL/min
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Table 2. Remission of idiopathic membranous nephropathy (IMN) in
various therapeutic strategies
Mean time to Remissiona
Therapeutic strategies Cases remission months rate (%)
No or supportive therapy 13 51.7 ± 10.5 7 (54%)
Immunosuppressive therapy
Steroids alone 15 45.0 ± 6.1 6 (40%)
Cyclophosphamide + steroids 24 52.6 ± 14.3 20 (83%)
Immunoglobulin ± steroids 29 32.4 ± 5.4 17 (59%)
Cyclosporine A ± steroids 20 14.9 ± 2.1 12 (60%)
Four cases of supportive therapy were excluded, because of less than 1.0 g/day
proteinuria during study. (mean ± SEM, Mantel-Cox log rank test, P = 0.1432).
aRemission defined as complete or incomplete remission type I (proteinuria
< 1.0 g/day).
vs. 95 mL/min), but statistically not significant. The
patients with ESRF showed heterogeneous type by elec-
tron microscopy, with the exception of one patient with
homogeneous type who developed ESRF due to drug-
induced tubulointerstitial renal injury. In the homoge-
neous type, remission was induced earlier in comparison
to the heterogeneous type (26 ± 4 months vs. 120 ±
13 months, P < 0.0001 in remission, 2% vs. 24%, P <
0.0001 in ESRF, respectively, Fig. 3A and B). The hetero-
geneous type also showed a poor prognosis for secondary
outcome after first biopsy, compared with the homoge-
neous type (Fig. 3C). When we analyzed clinicopathologic
factors such as age, gender, hypertension, GFR, clinical
state at biopsy (nephrotic or nonnephrotic), light micro-
scopic findings (total glomerular obsolescence, FSGS, in-
terstitial fibrosis, tubular atrophy, interstitial foam cells,
and arteriolosclerosis) and electron microscopic findings,
the clinicopathologic risk factors for ESRF that emerged
were electron microscopic findings, FSGS, interstitial fi-
brosis, arteriolosclerosis, and interstitial foam cells. The
risk factors for secondary outcome were FSGS, electron
microscopic findings, age, and arteriolosclerosis (Table 3).
The deep subgroup was also an independent risk fac-
tor for the secondary outcome in the homogeneous type
[N = 7 vs. other homogeneous type (N = 53), hazard ra-
tio 9.09, 95% CI 2.22 to 37.04, P = 0.0212]. Four patients
in the deep subgroup died, two from pneumonia during
immunosuppressive therapy, one from lung cancer with
pneumonia, and the other from gastric cancer, 28 and
52 months, respectively, after onset.
Changes in pathologic findings during
the follow-up period
Following therapy or at relapse, 52 patients underwent
a second or third renal biopsy at 1 to 201 months post-
treatment. No noticeable changes were seen in subep-
ithelial IgG or electron dense deposits in renal biopsies
carried out within 12 weeks of a course of intravenous
immunoglobulin therapy (N = 20). In the homogeneous
type of patients who underwent a second or third renal
biopsy after 6 to 72 months (N = 13), electron dense de-
positions changed phase from early to late, except for just
one case of transformation from homogeneous to hetero-
geneous type. A further eight patients who relapsed after
remission showed new subepithelial dense deposits char-
acteristic of the early phase of the homogeneous type,
but not the heterogeneous pattern. Thus a small minor-
ity of patients thought to be of the homogeneous type
may actually be in the early phase of the heterogeneous
type. In contrast, patients of the heterogeneous type (N =
11) displayed various phases of electron dense deposits
even in follow-up renal biopsies carried out from 12 to
201 months later.
Relationship between response to treatment and
the subtypes of membranous nephropathy
In the homogeneous type, there was no significant dif-
ference in the mean time of remission to a value of daily
proteinuria below 1.0 g in patients not receiving immuno-
suppressant (16.3 ± 2.7 months, N = 6), those receiving
steroid alone (20.7 ± 5.2 months, N = 6), cyclophos-
phamide with steroid (19.6 ± 6.2 months, N = 14), intra-
venous immune globulin with or without steroid (23.6 ±
7.3 months, N = 14), or cyclosporine with or without
steroid (11.8 ± 1.9 months, N = 16) (Mantel-Cox log rank
test, P = 0.8591). With regard to primary outcome in the
heterogeneous type, no difference was observed in 75%
renal survival time between patients treated with steroid
alone (84 ± 75 months, N = 9), cyclophosphamide with
steroid (161 ± 50 months, N = 10), or intravenous im-
mune globulin with or without steroid (167 ± 76 months,
N = 16) (Mantel-Cox log rank test, P = 0.6289).
DISCUSSION
The prognosis of patients with IMN is variable. In this
study, we have analyzed the different outcomes for two
distinct subtypes of IMN as defined by the electron dense
deposit pattern in the initial renal biopsies.
When we analyzed clinical factors in isolation, pro-
longed proteinuria over 1.0 g/day and decreased GFR
were independent risk factors for ESRF. These results
confirm the recent suggestion that prolonged protein-
uria itself may accelerate renal injury. Hence, protein-
uria should be maintained below 1.0g/day in human IMN.
Damaged renal function at initial biopsy, which may be
the result of prolonged disease, was also a risk factor for
the development of ESRF. Such cases should be iden-
tified at an early clinical stage and treated intensively.
According to this view, electron microscopic examina-
tion of the immune-complex deposition pattern may be
a useful tool for estimating disease activity and clinical
outcome. Ehrenreich et al [10] first described the evolu-
tion of glomerular capillary lesions in terms of four stages:
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Fig. 3. The outcomes of homogeneous and heterogeneous types of idiopathic membranous nephropathy (IMN). (A) The time course of clinical
improvement to incomplete remission type I (proteinuria below 1.0 g/day). (B) Renal survival rate in subtypes. (C) Renal or patient death in
subtypes by Kaplan-Meier life-table method. Broad and thin lines represent the heterogeneous type and homogeneous type, respectively.
Table 3. The multivariate Cox proportional hazard model of
clinicopathologic factor for primary and secondary outcome
Variables Hazard ratio 95%CI P value
Primary outcome
Electron microscopic deposit 0.04 0.003–0.64 0.0228
pattern (homogeneous)
Focal segmental 1.04 1.01–1.09 0.0274
glomerulosclerosis
Interstitial fibrosis 6.70 1.15–39.0 0.0343
Arteriolosclerosis 2.89 1.07–7.84 0.0369
Foam cell 1.90 1.02–3.55 0.0437
Secondary outcome
Focal segmental 1.05 1.02–1.08 0.0015
glomerulosclerosis
Electron microscopic deposit 0.20 0.06–0.72 0.0135
pattern (homogeneous)
Age 1.05 1.01–1.09 0.0175
Arteriolosclerosis 1.80 1.02–3.18 0.0428
Initial subepithelial dense deposits (stage I); a subsequent
basement membrane spike response (stage II); eventual
incorporation of the deposits within the glomerular base-
ment membrane (stage III); and finally formation of a
markedly thickened basement membrane (stage IV). Pa-
tients with a single generation of deposits showed restora-
tion of a normal glomerular basement membrane with
intramembranous lucencies, so called phase IV, when in
complete clinical remission. Stage IV lesions, according
to the definition of Ehrenreich et al [10], were observed
in only three cases of ESRF out of our total of 105 cases.
In the present study, we arbitrarily classified specimens
showing synchronous electron dense deposits of a single
phase as of homogeneous type, and others showing vari-
ous phases of electron dense deposits as of heterogeneous
type. Our finding that most patients of the homogeneous
type have good outcomes with respect to clinical and re-
nal function, suggests the usefulness of this arbitrary clas-
sification as a clinical indicator.
We hypothesized that immune activity is transient and
self-limiting in the homogeneous type, so that capillary
lesions are repaired and subepithelial electron dense de-
posits transformed from phase I to IV during clinical re-
mission. Nephritis caused by short period insults such as
Heymann nephritis in animal models, and human sec-
ondary membranous nephropathy caused by drugs such
as gold, show quite similar immune-complex deposition
patterns to those of the homogeneous type. In the hetero-
geneous type, on the other hand, immune activity is pro-
longed, and deposits of various phases therefore develop
during the repair of basement membrane. Unfortunately,
there is currently no experimental model of the hetero-
geneous type. We speculate that one reason the hetero-
geneous type developed ESRF is that the continuous and
repeated immune-complex deposition causes irreversible
glomerular capillary lesions. However, the precise nature
of these different immune responses, such as antigen ex-
posure or antibody production, is still unclear, and further
investigation is needed to resolve this question.
Our clinicopathologic study revealed that the hetero-
geneous pattern of electron microscopic findings is one
of the risk factors for ESRF and death. Hence, the het-
erogeneous type should be treated intensively to avoid
the development of ESRF. We could not identify differ-
ences in effectiveness between therapies for the hetero-
geneous type, although a tendency for improved renal
survival was seen with alkylating therapy and immune
globulin, as previously demonstrated by meta-analysis
[13]. Recent therapies such as methylprednisolone pulse
therapy with chlorambuchil [14] and steroid with cy-
closporine [15] induced early remission and prevented
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the decline of renal function in patients with steroid-
resistant IMN. Trials of new therapeutic regimens for the
heterogeneous type are desirable. If a good renal prog-
nosis, including spontaneous remission, can be achieved
with supportive therapy in the homogeneous type, in-
tensive treatments may not be needed. The subgroup
with deep deposits is an independent risk factor for
secondary outcome, however, because of the prolonged
severe nephrotic state combined with infection and ma-
lignant neoplasms. The nephrotic state complicated by
infection is an important cause of morbidity and mortal-
ity in patients with severe membranous nephropathy [5].
Intravenous immune globulin therapy is recommended in
the subgroup with deep deposits as it may reduce the risk
of infection as well as the duration of nephrotic periods,
as we reported previously [5, 11].
Other factors may influence progression to ESRF as a
result of IMN, as only some cases of the heterogeneous
type undergo this progression. The subgroup of the het-
erogeneous type with ESRF showed a higher percent-
age of FSGS, as previously reported by Wakai and Magil
[8]. We found, however, that interstitial lesions, including
foam cells, are also important factors in the multivariate
analysis. Macrophages are thought to transform into foam
cells by digesting modified low-density lipoprotein (LDL)
such as LDL that has been oxidized via scavenger recep-
tors. Foam cells play a significant role in atherosclerosis.
Interstitial foam cells are highly represented in nephrotic
syndrome and heredity nephropathies such as Alport syn-
drome [16, 17], but their exact roles in renal diseases re-
main unclear. Kurihara et al [18] reported that 51 out of
320 Japanese patients with IMN were positive for intersti-
tial foam cells that had undergone localized phenotypic
transformation, displaying mature macrophage charac-
teristics such as expression of 25F5 antigen and inter-
cellular adhesion molecule (ICAM)-1 [18]. In addition,
interstitial chemokine production may influence intersti-
tial lesions induced by macrophages and foam cells based
on genetic factors such as polymorphisms in the pro-
moter regions of chemokine genes, as recently reported
in chronic rejection of renal transplants [19]. Our findings
suggest that foam cells may induce prolonged interstitial
inflammation. Further studies may be needed to elucidate
the influence of other factors in the interstitial lesions
in IMN.
CONCLUSION
Electron microscopic findings as well as FSGS in the
first renal biopsy were useful indicators of primary and
secondary outcomes in IMN. The homogeneous type with
synchronous electron dense deposits, with the exception
of the deep subgroup, showed favorable long-term pri-
mary and secondary outcomes.
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